Welcome to our dedicated page for Kodiak Sciences SEC filings (Ticker: KOD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Kodiak Sciences Inc. filings document a Nasdaq-listed biotechnology issuer developing retinal medicines through its ABC Platform and related biologic programs. Recent Form 8-K reports record financial results, business highlights, clinical disclosures for Zenkuda, KSI-501 and KSI-101, and capital-structure events involving common stock.
Proxy materials describe annual meeting matters, shareholder voting procedures, executive compensation and equity award disclosures. Offering-related 8-K disclosures record the completed underwritten public offering of common stock, underwriting agreement terms, registered security details and related exhibits.
Kodiak Sciences Inc. Chief Financial Officer John A. Borgeson reported an exercise-and-sell transaction in company stock. He exercised stock options for 30,000 shares of common stock at an exercise price of $1.04 per share and acquired those shares. On the same date, he sold a total of 30,000 shares of common stock in open-market transactions at weighted-average prices of $34.01 and $34.67 per share, as disclosed in two sale entries. These sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 29, 2025. After these transactions, he directly holds 241,930 shares of Kodiak Sciences common stock.
Kodiak Sciences Inc. reported results of its 2026 annual meeting of stockholders held on June 2, 2026. Stockholders representing 55,026,544 shares, or 88.53% of the common stock entitled to vote, were present.
Three Class II directors — Charles A. Bancroft, Bassil I. Dahiyat, Ph.D., and Taiyin Yang, Ph.D. — were elected to serve until the 2029 annual meeting or until their successors are elected and qualified. Support ranged from 38,940,529 to 49,192,610 votes "for," with broker non-votes recorded on each item.
Stockholders approved, on an advisory basis, the compensation of the named executive officers, with 49,157,143 votes for, 323,196 against and 21,005 abstentions. They also ratified the appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 54,716,676 votes for, 52,962 against and 256,906 abstentions.
KOD filed a Rule 144 notice reporting proposed sales of 30,000 shares. The form states the securities are Common stock and lists an Exercise of Stock Options with an intended sale of 30,000 shares on 06/04/2026 for cash. The filing also notes a prior 10b5-1 sale by John Borgeson on 04/02/2026 of 30,000 shares for $1,197,453.00.
Sirenia Capital Management and Alex Silverstein reported beneficial ownership of 3,495,000 shares of Kodiak Sciences Inc. Common Stock, representing 5.7% of the class. The percentage is calculated using 61,847,870 shares outstanding as of March 19, 2026, per the company's Form 10-K. The filing states the shares are held by SILV Fund, Ltd., managed by Sirenia; Sirenia and Mr. Silverstein filed jointly under Rule 13d-1(k).
The cover page shows shared voting and dispositive power over the 3,495,000 shares. Signatures are dated May 15, 2026.
Kodak Sciences Inc. (KOD) remains a precommercial retina-focused biotech, reporting a net loss of $58.2 million for the quarter ended March 31, 2026, on operating expenses of $59.8 million. Research and development was $48.5 million, driven by late-stage programs Zenkuda (tarcocimab), KSI-501 and KSI-101, while general and administrative costs fell to $11.2 million as prior lease impairment and higher stock-based compensation rolled off.
Cash and cash equivalents were $169.5 million, with total assets of $306.0 million and a $100.0 million liability related to the sale of future royalties. Operating cash burn was $40.0 million in the quarter. The company has an accumulated deficit of $1.62 billion and discloses that its financial condition raises substantial doubt about its ability to continue as a going concern, even as it plans additional financing to support Phase 3 trials and prospective biologics license applications in diabetic retinopathy, retinal vein occlusion, wet AMD and macular edema secondary to inflammation.
Kodiak Sciences reported first quarter 2026 results and highlighted major progress in its retina drug pipeline. In the GLOW2 Phase 3 study in diabetic retinopathy, Zenkuda achieved a ≥2-step DRSS improvement in 62.5% of treated patients versus 3.3% on sham and cut sight‑threatening complications to 2.4% versus 15.8% on sham, supporting a multi‑indication BLA‑ready profile.
The company expects topline DAYBREAK Phase 3 wet AMD data for Zenkuda and KSI‑501 in Q3 2026, PEAK MESI data in Q4 2026, and PINNACLE MESI data in Q2 2027. Kodiak ended the quarter with $169.5 million in cash and cash equivalents and recorded a net loss of $58.2 million (basic and diluted loss of $0.94 per share), driven by $48.5 million in R&D and $11.2 million in G&A expenses. Management believes this cash will fund operations into 2027.
Kodiak Sciences Inc reports that BlackRock, Inc. beneficially owned 3,273,386 shares of Common Stock, representing 5.3% of the class as of 03/31/2026. The filing shows BlackRock has sole voting power for 3,221,479 shares and sole dispositive power for 3,273,386 shares. The schedule is signed by a BlackRock managing director on 04/27/2026.
Kodiak Sciences Inc. is soliciting proxies for its 2026 Annual Meeting, a virtual-only event on June 2, 2026. Stockholders of record on April 6, 2026 will vote on electing three Class II directors, an advisory say-on-pay resolution, and ratifying PricewaterhouseCoopers LLP as auditor.
The proxy describes a staggered, largely independent seven-member board, with directors and related options owning 29,786,724 shares, or 43% of common stock as of March 31, 2026. Executive pay is heavily performance-based: in 2025 about 68% of CEO and 65% of CFO compensation was at risk, and both received bonuses equal to 150% of target after exceeding clinical, regulatory, pipeline and financing goals. Kodiak outlines plans to file a Biologics License Application in diabetic retinopathy, retinal vein occlusion and wet AMD in 2026 and highlights multiple Phase 3 programs and an AI-enabled retinal imaging headset.
Kodiak Sciences Inc. Chief Financial Officer John A. Borgeson exercised stock options to acquire 28,614 shares of common stock at an exercise price of $1.04 per share. Following the transaction, he directly owns 211,930 common shares and holds options for 30,000 additional shares. The options exercised were already fully vested, indicating this was a routine compensation-related exercise rather than an open-market purchase or sale.